Chemogenomics can be defined as the study of genomic responses to chemical compounds. The goal is the rapid identification of novel drugs and drug targets embracing multiple early phase drug discovery technologies ranging from target identification and validation, over compound design and chemical synthesis to biological testing and ADME profiling.
In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.
With a shortage of new tuberculosis drugs in the pipeline, a software tool from the University of Michigan can predict how current drugs--including unlikely candidates--can be combined in new ways to create more effective treatments.
Drug discovery is in essence the designing of compounds to interact with disease-related proteins. And in many recent development efforts, this process increasingly relies on "big data" and complex "deep learning", requiring the harnessing of supercomputing power.
Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.
Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.
The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL's European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain.
A novel invention developed by a scientist from New York Institute of Technology (NYIT) could revolutionize biological and clinical research and may lead to treatments for cancer, AIDS, Alzheimer's, diabetes, and genetic and infectious diseases.